Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

State universities are big players in technology who often aggressively license research breakthroughs in fields such as biotechnology to companies, sometimes reaping millions in royalties. This complex intersection of public and private interests is rife with disputes over patent rights and inventions. And experts argue that a June ruling by the U.S. Supreme Court that citizens and companies can’t sue states in federal court over intellectual property could give the universities a decided edge in such legal battles.

The decision has already had an impact on at least one highprofile patent dispute.According to Martin Simpson, counsel for the University of California (UC), the ruling “obliterated”a lawsuit against the school by Genentech, a San Francisco biotech company. Genentech had been trying to void a UC patent the university
says covers recombinant human growth hormone, a drug that racked up $214 million in sales for Genentech last year. John Kidd, Genentech’s lead litigator and a partner in the New York law firm of Rogers & Wells, says firms who want to sue a state will now have to take their case to state court, where there’s no established forum for patent law.”I’ve got no place to sue,”laments Kidd.

Companies say that’s unfair because the Supreme Court decision leaves states free to sue them in federal court. In the Genentech/UC litigation, the university is countersuing Genentech for $1.2 billion, claiming the company stole key DNA code from a university lab.That case is unaffected by the Supreme Court decision.
Given the court’s ruling, it would seem that state universities can continue to dish out lawsuits, but no longer have to take them.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me